# Anika Therapeutics share price today (Anika Therapeutics, Inc., ANIK)

> Anika Therapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. ANIK · Healthcare · Drug Manufacturers - Specialty & Generic · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/anik

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $19.45 (+99.5% in a year)
- Revenue (Jun 2026): $32.6 M (+15.6% on a year ago)
- Profit (Jun 2026): $3.3 M
- Operating margin: 11.4% (+26.2 points on a year ago)
- ROE: −8%, FY25
- ROIC: −2.1%, against a 4.9% cost of capital: −7.0 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Anika Therapeutics share price today? Anika Therapeutics, Inc.'s share price was $19.45 at the close on 3 November 2026. That is 20.3% above its average price over the last 200 trading days. In the last 52 weeks it traded between $9 and $22, and at that close it sat 81% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 1 week running. Over the last 1 year the share price moved +73% while the S&P 500 moved +21%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 30 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Anika Therapeutics pay? Anika Therapeutics, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Anika Therapeutics on? Anika Therapeutics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Anika Therapeutics profitable? Anika Therapeutics, Inc. earned $3.3 M of net profit in the Jun 2026 quarter. The full FY25 year was a loss of $10.9 M. That is 10.1% of the quarter's revenue. The same quarter a year earlier lost $4.0 M. 10 of the last 12 reported quarters were loss-making. ## How much revenue does Anika Therapeutics make, and is it growing? Anika Therapeutics, Inc. reported $32.6 M of revenue in the Jun 2026 quarter, +15.6% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 4 years it has grown −6.5% a year on average. The last full year, FY25, came in at $113 M. The last four reported quarters add to $121 M. The quarterly figures for FY22 do not add up to the full-year total on file, so those quarters are left out of the charts and sums. FY25 revenue was $113 M, −5.9% on the year before. Recent pace: the last four quarters grew +5.7% on average, against −6.5% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +5.3%, against −8.9% a year over the last 8 quarters (accelerating). ## How much of every $100 of sales does Anika Therapeutics keep? Anika Therapeutics, Inc.'s operating margin was 11.4% in the Jun 2026 quarter, 26.2 percentage points higher than the same quarter a year ago. Across 5 years it has been between −9.8% and 3.2%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +26.2 percentage points on the year while gross margin changed +14.2 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Anika Therapeutics' profit turning into cash? Anika Therapeutics, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 it brought in $11.2 M of operating cash against −$10.9 M of profit. After $6.8 M of spending on assets, $4.4 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Anika Therapeutics' cash go? Anika Therapeutics, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $20.0 M on assets over the last 3 years. Averaged over those years that is 5.9% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $20.0 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Anika Therapeutics' P/E ratio, and how does it compare with its own history? Anika Therapeutics, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Anika Therapeutics, Inc. at 2.3× its FY25 revenue of $113 M. The P/E comes back here once profit turns positive. ## Is the Anika Therapeutics business getting better or worse? Anika Therapeutics, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 9 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Anika Therapeutics earn on its capital? Anika Therapeutics, Inc. earned a ROE of −8% in FY25. That is up from a low of −39% in FY23. Its return on capital used (ROIC) is 7.0 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −9.6% net margin and 0.59× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −9.6% net margin × 0.59× asset turnover × 1.33× leverage (assets divided by equity) ≈ −7.5% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: −2.1% − 4.9% = −7.0 percentage points. The 4.9% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The −2.1% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at −9.3%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Anika Therapeutics have too much debt? Anika Therapeutics, Inc. has total debt of $25.3 M against shareholder equity of $137 M as of Jun 2026, so its debt is 0.18× its equity, which is very little. Year by year, that ratio went from 0.07 in FY21 to 0.18 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Anika Therapeutics shareholding pattern? 3.2% of Anika Therapeutics, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 3.8 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Anika Therapeutics from balance-sheet trouble? For Anika Therapeutics, Inc., the Z-score is 3.62. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 3.62 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Anika Therapeutics rank in its industry? There is no score against its industry: Anika Therapeutics, Inc. is not among the largest members shown in this industry comparison for Drug Manufacturers - Specialty & Generic. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Anika Therapeutics compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Anika Therapeutics in size? Anika Therapeutics is the 46th largest of 51 Drug Manufacturers - Specialty & Generic companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Aurora Cannabis Inc., Emergent BioSolutions Inc. and Canopy Growth Corporation. Just below it: Lifecore Biomedical, Inc., SIGA Technologies, Inc. and Akebia Therapeutics, Inc. ### Drug Manufacturers - Specialty & Generic companies close in size

1. [Aurora Cannabis Inc.](https://www.sectoralpha.in/us/stocks/acb) $339 million
2. [Emergent BioSolutions Inc.](https://www.sectoralpha.in/us/stocks/ebs) $320 million
3. [Canopy Growth Corporation](https://www.sectoralpha.in/us/stocks/cgc) $302 million
4. Anika Therapeutics, Inc. $260 million
5. [Lifecore Biomedical, Inc.](https://www.sectoralpha.in/us/stocks/lfcr) $243 million
6. [SIGA Technologies, Inc.](https://www.sectoralpha.in/us/stocks/siga) $223 million
7. [Akebia Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/akba) $201 million

[All 51 Drug Manufacturers - Specialty & Generic companies, largest first](https://www.sectoralpha.in/us/sectors/drug-manufacturers-specialty-generic#all-companies)

### Companies close in size in other industries

1. [Lantronix, Inc.](https://www.sectoralpha.in/us/stocks/ltrx) $281 million · Communication Equipment
2. [Nano Dimension Ltd.](https://www.sectoralpha.in/us/stocks/nndm) $280 million · Computer Hardware
3. Anika Therapeutics, Inc. $280 million
4. [InfuSystem Holdings, Inc.](https://www.sectoralpha.in/us/stocks/infu) $280 million · Medical Devices
5. [Virginia National Bankshares Corporation](https://www.sectoralpha.in/us/stocks/vabk) $280 million · Banks - Regional

## What else do people ask about Anika Therapeutics? ### What were Anika Therapeutics's latest quarterly results? Anika Therapeutics, Inc. reported revenue of $32.6 M and net profit of $3.3 M for the Jun 2026 quarter. Earnings per share were $0.24. The operating margin was 11.4%, 26.2 percentage points higher than a year earlier (as of 3 November 2026). ### What is Anika Therapeutics's market cap? Anika Therapeutics, Inc.'s market capitalisation is $260 M at a stock price of $19.45. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Anika Therapeutics performing? Anika Therapeutics, Inc.'s latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 1 week running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Anika Therapeutics's stock price go up? This page does not forecast Anika Therapeutics, Inc.'s stock price. What it shows instead: the stock price is $19.45. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is Anika Therapeutics in its business cycle? Anika Therapeutics, Inc.'s FY25 operating margin was −9.8%, against a 5-year range of −9.8% to 3.2%: the low end of its own range, which is often where recoveries start. The latest quarter was 11.4%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Anika Therapeutics story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Anika Therapeutics a stock worth studying right now? What the numbers show: Anika Therapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.